Extended observation for adverse reactions following subcutaneously administered trastuzumab (Herceptin, Genentech/Roche) serves as an unnecessary use of health care resources, according to the results of a single-institution study.
Common menopausal symptoms such as nausea and headaches can be used as predictive tools for adherence to the aromatase inhibitor tamoxifen, according to an analysis of data from the International Breast Cancer Intervention Study (IBIS-1).
A study presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL) has found that the costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness.
Patients with human epidermal growth factor 2 (HER2)-positive breast cancer who undergo induction chemotherapy are likely to convert to HER2-negative disease if residual disease occurs, prompting further systemic therapy, according to research presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).
Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer benefit from an estimated 7 additional months of survival if treated with trastuzumab emtansine rather than the physician’s choice of therapy, according to research published in The Lancet Oncology [published online May 16, 2017; doi:10.1016/S1470-2045(17)30313-3].
A radiation schedule half the standard course is as safe and effective for patients with breast cancer following a mastectomy, according to a study published in the Journal of Clinical Oncology (published online May 1, 2017; doi:10.1200/JCO.2016.70.7158).
MRI results after percutaneous biopsy for ductal carcinoma in situ (DCIS) often overestimate the extent of breast cancer, resulting in unnecessary mastectomies, according to a presentation at the American Society of Breast Surgeons annual meeting (April 26-30, 2017; abstract 257324).